This analysis revealed that high TXNDC12 expression consistently correlated with worse overall survival in patients with cervical squamous cell carcinoma, esophageal carcinoma, acute myeloid leukemia, lower grade glioma, liver hepatocellular carcinoma, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, mesothelioma, sarcoma, thyroid carcinoma and uveal melanoma (Supplementary Fig. 1). This evidence concerns the gene TXNDC12 and thyroid gland carcinoma.